N/A
N=13
Proton Therapy for Unresectable Cancer (CA) of Pancreas
Pancreatic Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00685763 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcome: Primary: Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start) — 0 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Proton radiation and chemotherapy (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- Oct 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start) |
— | — |
| SECONDARY Collect and Analyze Tumor Control Measures |
— | — |
Summary
The purpose of this study is to find out what effects, good and/or bad, proton radiation and chemotherapy has on you and your pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
Pathologically confirmed adenocarcinoma of the pancreas.
Patients must be medically inoperable or have unresectable disease
Exclusion Criteria
- Evidence of distant metastasis; evidence of metastatic disease in the major viscera (organs), peritoneal seeding and/or ascites.
- Previous irradiation to the abdomen that would compromise the ability to deliver the prescribed treatment.
- Prior surgical resection.
Data sourced from ClinicalTrials.gov (NCT00685763). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.